Certain markers, such as CD38, CD138 (SDC1), CD269 (BCMA, TNFRSF17) and CD49d (ITGA4) are characteristic of MM primary cells and HMCLs, making them potential targets for therapy8. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.